Form 4: AnaptysBio CEO Daniel Faga Reports Stock Transactions
SEC Form 4
AnaptysBio's CEO, Daniel Faga, reports the vesting of restricted stock units, acquisition of shares under the ESPP, and related tax withholding transactions.
Summary
- Daniel Faga, CEO of AnaptysBio, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
- On January 3, 2025, 34,678 restricted stock units (RSUs) vested, resulting in the acquisition of 34,678 shares.
- Additionally, 212 shares were acquired under the company's Employee Stock Purchase Plan (ESPP).
- The company withheld 13,033 shares to cover tax obligations related to the RSU vesting at a price of $14.6 per share.
- On January 6, 2025, another 17,850 RSUs vested, resulting in the acquisition of 17,850 shares.
- The company withheld 6,387 shares to cover tax obligations related to the RSU vesting at a price of $15.3 per share.
- On January 7, 2025, 107,350 RSUs were granted, vesting annually commencing on January 7, 2026.
- A stock option to purchase 305,500 shares was granted on January 7, 2025, vesting 25% on January 7, 2026, and then monthly until fully vested, with an exercise price of $14.83.
- Following these transactions, Faga directly owns 436,466 shares of AnaptysBio common stock.
Sentiment
Score: 6
Explanation: The document is a standard regulatory filing, indicating routine transactions. The sentiment is neutral, reflecting standard executive compensation practices.
Positives
- The vesting of RSUs and acquisition of shares through the ESPP indicate continued alignment of the CEO's interests with those of the shareholders.
- The grant of stock options provides further incentive for the CEO to drive long-term value creation.
Future Outlook
The RSUs and stock options vest over time, contingent on the Reporting Person's continued service to the Issuer.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Comparison to Industry Standards
- Executive compensation packages often include a mix of salary, stock options, and restricted stock units to align management's interests with those of shareholders.
- The vesting schedules for RSUs and stock options are typical, designed to incentivize long-term performance.
- Tax withholding practices related to RSU vesting are standard procedure.
Stakeholder Impact
- The transactions reported in the Form 4 provide transparency to shareholders regarding the CEO's holdings and incentives.
- The vesting of RSUs and grant of stock options incentivize the CEO to create long-term value for shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/03/2025 | Vesting of 34,678 Restricted Stock Units and acquisition of shares under the Company's ESPP |
| 01/03/2025 | Shares withheld by the Issuer to satisfy a portion of the tax withholding obligation in connection with the vesting of RSUs |
| 01/06/2025 | Vesting of 17,850 Restricted Stock Units |
| 01/06/2025 | Shares withheld by the Issuer to satisfy a portion of the tax withholding obligation in connection with the vesting of RSUs |
| 01/07/2025 | Grant of 107,350 Restricted Stock Units |
| 01/07/2025 | Grant of stock option (right to buy) 305,500 shares |
| 01/06/2035 | Expiration date of stock option |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.